Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / AXSM
Stock rating
Axsome Therapeutics, Inc (AXSM) Stock Rating & Analysis
As of September 29, 2026, MELANY rates Axsome Therapeutics, Inc 54 out of 100 (Promising). Its highest factor score is risk-adjusted profile at 75, and its lowest is business quality at 28.
MELANY ratingRated 2026-09-29AXSM · composite score
Why AXSM scores 54/100
AXSM's 8 factor scores run from 28 to 75, and 2 of them sit above its composite of 54. Here is how AXSM breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 93%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
- Analyst targets 53% upside
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How AXSM compares
As of October 7, 2026, Axsome Therapeutics, Inc ranks 18th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Key risks for AXSM
- High debt-to-equity ratio 2.7x, rate-sensitive balance sheet
- Operating margin -24%, cash-burn business, dependent on capital markets
- Negative free cash flow, company consuming cash, not generating it
- Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Axsome Therapeutics, Inc sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 76/100 for strength. Theme strength feeds AXSM's momentum and catalyst factors above.
AXSM trade plan (Pro)
MELANY has a full position plan for Axsome Therapeutics, Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates AXSM
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Axsome Therapeutics, Inc's 54/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about AXSM
Is Axsome Therapeutics, Inc (AXSM) a buy?
As of 2026-09-29, MELANY rated Axsome Therapeutics, Inc Promising with a composite score of 54/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Axsome Therapeutics, Inc's MELANY score?
Axsome Therapeutics, Inc (AXSM) has a MELANY composite score of 54/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the AXSM stock rating calculated?
MELANY scores AXSM from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Axsome Therapeutics, Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Axsome Therapeutics, Inc (AXSM) Promising with a composite of 54/100 as of 2026-09-29. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the AXSM stock price forecast?
MELANY does not publish price targets or forecasts for AXSM. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 54/100 across eight factors for Axsome Therapeutics, Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is AXSM stock overvalued or undervalued?
MELANY's valuation factor currently reads 35/100 for Axsome Therapeutics, Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives AXSM's read.
What price should I buy AXSM at?
Rather than chasing the current price, MELANY computes a smart entry zone for AXSM: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying AXSM stock?
The top risks MELANY currently flags for Axsome Therapeutics, Inc: High debt-to-equity ratio 2.7x, rate-sensitive balance sheet; Operating margin -24%, cash-burn business, dependent on capital markets; Negative free cash flow, company consuming cash, not generating it; Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Axsome Therapeutics, Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 28/100 for Axsome Therapeutics, Inc, and earnings track record, at 31/100. The 54/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will AXSM stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 47/100 for AXSM right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this AXSM rating?
The rating on this page is a snapshot of MELANY's read as of 2026-09-29. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores AXSM continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, AXSM included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.